Objective To study the associations between intake of various types of fat and risk of prostate cancer (PCa) in a population-based cohort. Methods We have studied 10,564 initially cancer-free men of the Malmö Diet and Cancer cohort, aged 45-73 years. Diet was assessed by a modified diet history method. Cases and clinical characteristics were ascertained via national and regional registry data. Results During a mean follow-up of 11.0 years, 817 incidental PCa cases were diagnosed. Out of these, 281 were classified as advanced. There were 202 cases occurring before 65 years of age. After adjustment for age and energy intake, there was no association between intake of any types of fat and risk of PCa, or between fat intake and advanced PCa or PCa occurring in persons aged\65 years.
Introduction
Prostate cancer is the third most common cancer in men globally; it represents almost 10% of all cancer cases. However, both incidence, prevalence and mortality vary considerably between countries and populations; e.g., in the Western world, it is the most common male cancer [1] [2] [3] .
Several studies have reported positive associations between a high intake of total and saturated fat and incidence of prostate carcinoma. Similar claims have been made for polyunsaturated fatty acids (PUFA) [2, 4, 5] . However, methodological weaknesses and differences among studies (retrospective designs, lack of adjustment for total energy intake, inadequate diet assessment methods, or no calculations of actual fat intake [4] ) make many of these results difficult to interpret. Among epidemiological studies that have avoided these design problems [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] , results have been mixed.
Concerning PUFA, a growing body of evidence suggests that the associations of individual fatty acids (FA) with prostate cancer are different from one another. For example, a recent study from Finland observed decreased risk in persons with higher serum levels and dietary intakes of linoleic acid (LA; cis-18:2, x-6) [14] . This was in agreement with a case-control study that examined adipose tissue fatty acid composition, which is reported to be a good marker of long-term intake [9] . However, most previous evidence speaks against any association [8, 10, 11, 13, 15, 16] . a-linolenic acid (ALA; 18:3, x-3) has in some studies been a relatively strong predictor of cancer risk [6, [8] [9] [10] 15] , but has shown no association in others [13, 14] , and a meta-analysis [17] concluded that the heterogeneity between studies was too large for proper evaluation. Longchain x-3 FA (mainly eicosapentaenoic acid (EPA; 22:5) and docosahexaenoic acid (DHA; 22:6)), of which the dominant source is fatty fish, were associated with lower risk in some studies [14, 15] , but not in others [6, 8, 10, 13] . Similarly, fish consumption per se appeared protective in some studies [18] [19] [20] , but not in all [13, 16, 21] .
Further, some researchers argue that dietary fat, e.g., ALA, may be more strongly associated with more aggressive tumors than with indolent tumors [15] . Similarly, it is often hypothesized that there are differences among factors associated with tumors occurring at younger and older ages (e.g., [22] [23] [24] .
We here present the results from an examination of these issues, based on a 11-year follow-up of a populationbased cohort in Malmö, Sweden.
Methods

Study population
The Malmö Diet and Cancer (MDC) study is set in Malmö, Sweden's third largest city [25] . The background population consisted of all men born between 1923 and 1945 and all women born between 1923 and 1950 who were living in Malmö during the screening period 1991 to 1996 (n = 74,138). This population was identified through the Swedish national population registries. The final cohort consisted of 28,098 individuals (participation rate 40.8%). The subjects were recruited through advertisements in local media and through invitation by mail. The only exclusion criteria were inadequate Swedish language skills and mental incapacity [26, 27] . The Ethics Committee at Lund University approved the design of the MDC study (LU 51-90).
Data collection
The study subjects visited the MDC study center twice. At the first visit project staff provided information on the background and aim of the project, and detailed instructions about the dietary assessment and the other procedures of the study, including the lifestyle questionnaire. Height and weight were also measured. At the second visit, a dietary interview was performed (see below), and the lifestyle questionnaires were checked for incomplete answers.
Dietary assessment
The MDC study used an interview-based, modified diet history method that combined (i) a seven-day menu-book for registration of lunch and dinner meals, cold beverages including alcohol, drugs, natural remedies, and nutrient supplements, (ii) a 168-item questionnaire for assessment of meal pattern, consumption frequencies and portion sizes of regularly eaten foods, and (iii) a 45-min complementary interview. The consistency of the information provided was carefully checked so that the questionnaire and menu-book did not overlap.
The mean daily intake of foods was calculated based on frequency and portion size estimates from the questionnaire and menu-book. The food intake was converted to energy and nutrient intakes using the MDC nutrient database, wherein the majority of the nutrient information comes from PC-KOST2-93 (National Food Administration, Uppsala, Sweden). The method is elsewhere described in more detail [28] .
Data on the validity [29, 30] and reproducibility [31] In September 1994, the coding procedures of the dietary assessment were slightly altered in order to reduce interview time. An evaluation of these changes has been published [28] ; it was shown that the effects of the alterations were very small. We still chose to adjust for this alteration in the analyses, as described below.
Case ascertainment and staging Cancer cases were ascertained by record linkage with the National Cancer Register. Cancer cases from the year 2005, and additional data on tumor stage and grade, prediagnostic serum PSA value, and reason for diagnosis (symptoms, health examination, or other) was obtained from the National Prostate Cancer Register (NPCR) (South Region). In the South Region, to which Malmö belongs, registration was started in 1996. For cases diagnosed between 1991 and 1995, the same data was manually extracted from medical records using standard routines. The South Region register is at least 95% complete; the National Cancer Register is known to be at least 98% complete. A validation of the NPCR data from another region showed high validity for all variables, including the variables used in the classification of non-advanced and advanced tumors [32] .
There are 11,063 men in the MDC cohort. Among these, 485 men were already diagnosed with cancer (excluding basal cell carcinomas) when entering the study, and were therefore excluded from further analysis. A total of 14 other men were excluded because of obtaining a diagnosis of prostate cancer at autopsy. This left 10,564 men for analysis. They were followed until date of death, date of prostate cancer diagnosis, or 31 December, 2005, whichever came first. No participants were lost to follow-up of vital status. Among them, 817 incident cases of prostate cancer (''total prostate cancer''; ICD-9 code 185) occurred from the time of the baseline examinations until the end of follow-up. The average follow-up time in participants free of prostate cancer at death (n = 1,321) or at the end of follow-up (n = 8,426) was 11.0 years.
An advanced case (''advanced prostate cancer'') was defined as a having a tumor with a clinical T stage of three or higher or tumor-positive lymph nodes (N1) or one or more distant metastases (M1) or a Gleason score of 8 or higher or a pre-treatment serum prostate specific antigen (PSA) value of at least 50 ng/mL [24] . Tumors were also classified as advanced if WHO grade was three, and Gleason score was unavailable (n = 6). In cases where at least two of T stadium, Gleason score or PSA serum value was reported, and none of these factors indicated an advanced tumor, the tumor was classified as non-advanced. We thus defined 281 incident cases as being advanced, and 530 cases as non-advanced. Staging data was unavailable or insufficient for six of the incident cases. These six cases, and the 530 cases of non-advanced cancers, were excluded from analyses comparing men with advanced tumors with other men.
In order to analyze prostate cancer occurring in younger people, we repeated all analyses in a sub-cohort, where the end of follow-up occurred either at date of death, date of prostate cancer diagnosis, 31 December, 2005, or the man's 65th birthday, whichever came first. This younger subcohort consisted of 8,194 men, among whom 202 incident prostate cancers (54 advanced) occurred. Mean follow-up time for non-cases was 7.7 years.
Dietary variables
The dietary variables used in this study were mean daily intakes of dietary total energy, fat, saturated FA, monounsaturated FA, polyunsaturated FA, palmitoleic acid, oleic acid, LA, ALA, AA, EPA, DHA, the sum of EPA and DHA, sum of x3 FA (20:5 + 22:5 + 22:6 + 18:3) and x6 FA (20:4 + 18:2), and the x3:x6 intake ratio. Calcium intake, and consumption of red meat, fruits, and vegetables were included, as potential confounders. Intake from EPAand DHA-containing supplements were included in some analyses, for which variables on total EPA and DHA intakes were created.
In the statistical analyses, the food and nutrient variables were adjusted for total energy intake (residual method) [33] . This procedure allows comparison of intakes independently of energy requirements, and also diminishes the influence of measurement errors [33, 34] .
Other variables
A structured multiple-choice questionnaire was used in the MDC study to collect information on sociodemographic factors, smoking status, alcohol habits, health status, and several other factors. The agreement between the baseline questionnaire and the same questionnaire when repeated after three weeks was high for most variables (kappa values [ 0.75) [27] .
Statistical methods
We have examined the associations between prostate cancer incidence (total, advanced, and occurring before age 65 y) and intake of groups of fatty acids, and of individual fatty acids. The energy-adjusted intake variables were divided into quintile groups. The hazard ratios of each distribution quintile (compared to the lowest), and trends across the quintile, were assessed with Cox' proportional hazards regression, with adjustment for age at baseline. The time variable was number of days of follow-up after baseline. All fat analyses were stratified on dietary assessment method version.
We then repeated the analyses above with adjustment for a number of potential confounders (age, diabetes, waist circumference, height, living alone/with partner/ with other, educational level, alcohol habits, BMI, smoking history, birth country (Sweden/other), total calcium intake, consumption of fruits, vegetables, and red meat) selected from a survey of the current scientific literature.
All EPA-and DHA-related analyses were repeated with the inclusion of intake of EPA and DHA from supplements.
In a series of sensitivity analyses, we repeated all analyses after exclusion of men who reported having changed dietary habits (630 cases remaining), cases in which the cause of the diagnosis was not symptoms (478 cases remaining), persons not born in Sweden (748 cases remaining), persons who were considered to be misreporters of total energy intake (as described previously [35] ) (714 remaining cases) and cases occurring within two years of the beginning of follow-up (691 remaining cases). We also analyzed the effect of adjustment for dietary interviewer and season of dietary interview.
We also performed Cox regressions in which age (in quarters of years) was used as a stratification variable, with adjustment for the year of entry into the cohort, in order to assess the effects of using a more thorough adjustment for age.
Statistical tests resulting in p values lower than, or equal to, 0.050 were considered statistically significant. All statistical analyses were performed with SPSS for Windows, version 12.0.1 (SPSS Inc., Chicago, IL, U.S.A.). Table 1 shows the ages of the cases and non-cases, and some clinical characteristics of the tumors. In the entire cohort, cases were older than non-cases at the start of the study, particularly men with advanced disease. In the younger sub-cohort, cases were younger than non-cases.
Results
The associations between the risk of prostate cancer, and the different dimensions of fat intake, are given in Table 2 . Higher intake of EPA and DHA, alone or in combination was associated with increased total risk of prostate cancer. For example, the hazard ratio for highest vs. lowest quintile of DHA was 1.35 (95% confidence interval (CI) 1.07-1.69; p for trend = 0.021). No other examined dimension of fat intake was significantly associated with total prostate cancer risk. After adjustment for potential confounders, the risk estimates between EPA and DHA and total prostate cancer risk were similar, but the associations were weaker ( Table 2 ). EPA and the sum of EPA and DHA were no longer significant (p for trend = 0.067 and 0.063, respectively).
None of the fat intake variables were significantly associated with risk of advanced or younger prostate cancer (Tables 3-4) .
The number of men who used EPA/DHA supplements at least once during the seven-day registration period was 327. There were no statistically significant differences in frequency of supplement use among cases, advanced cases and non-cases (Fisher's exact test, data not shown). Adding the supplemental intake from the 327 men to the dietary data did not change the results on total prostate cancer to any great extent, neither in the age-adjusted analysis, nor in the multivariate analysis (Table 5 ). The same was true of the analyses featuring advanced cases and younger cases (data not shown).
Sensitivity analysis
Exclusion of asymptomatic cases resulted in slightly higher risk estimates for increasing intakes of age-adjusted DHA (RR for highest quintile of DHA = 1.49, 95% CI 1.10-2.02; p = 0.018) with total prostate cancer. The same was true of the EPA + DHA combination (data not shown). Exclusion of cases occurring within two years of the beginning of follow-up resulted in virtually unchanged results for these fatty acids, only with slightly higher p values. However, all other exclusions (men who changed dietary habits, men not born in Sweden, and men who were considered to be misreporters of total energy intake) yielded weaker, non-significant trends for these and other fat intake variables. This was also true of the sensitivity analyses featuring adjustments for multiple potential confounders.
Adjustment for interviewer and season of dietary interview did not change the results appreciably (data not shown).
The age-and energy-adjusted results on dietary and supplementary EPA/DHA and total prostate cancer (Table 5) were slightly more robust than the corresponding data without supplements (Table 2) ; they remained significant even after exclusion of cases without symptoms, cases occurring within two years of follow-up and (for EPA only) persons who had changed their diet (data not shown).
Using age (in quarters of years) as a stratification variable (as described above) did not change the results appreciably (data not shown).
Discussion
Total and saturated fat intake are often considered established risk factors of prostate cancer, although they were judged to be only ''possible'' causes of increased risk in a major review [36] . Few studies with validated methods and adequate energy adjustment have confirmed this association [6, 15] . We found no association between intake of total, saturated or mono-unsaturated fat and risk of prostate cancer, in spite of high relative validity, good power and reasonably wide ranges of intake (the 95th percentiles being circa three times greater than the fifth for the major FA groups; not shown). The upper limit of the 95% CI for the relative risk estimates for the highest quintile of total and saturated fat intakes was only 1.19. Considering the CIs for the other quintiles, this translates into a maximum attributable fraction for saturated fat of about four percent [37] . This, in turn, implies that a major role of these nutrients in prostate cancer etiology is unlikely; although it is plausible that non-differential misclassification due to measurement errors deflates this number.
We have observed positive associations between EPA/ DHA intakes and risk, although the current literature generally points towards either no association or inverse associations [4, 15, 38] . The meta-analysis by Dennis et al. [17] also reported a positive association; however, this result was based on two studies only, none of which reported statistically significant trends [12, 13] . Further, since the publication of this meta-analysis, at least two studies have reported significant inverse associations [15, 20] . The associations in our study were rather weak, but quite robust. For example, they were only slightly weakened by multiple adjustments for potential confounders ( Table 2 ). The associations disappeared after most relevant exclusions (see above), but not consistently. It could also be argued that the disappearing associations are partly the effect of lower power due to fewer cases, since the estimates were often similar to the ones in the main analyses. On the other hand, we have not been able to find any reports of experimental work claiming EPA or DHA to be involved in prostate carcinogenesis. EPA and DHA in the diet originates almost exclusively from fatty fish. It may be worth noting that fatty fish, not least from the Baltic Sea, is a source of environmental toxins, such as polychlorinated biphenyls (PCBs) [39] , which are known to disrupt estrogen, androgen, and other endocrine systems [40] . There are reports associating PCB exposure with risk of prostate cancer [41] , which means that the EPA/DHA-prostate cancer association could be confounded by environmental toxins. Further, in a recent prospective study from Japan, a country with traditionally high fish consumption, fish consumption was associated with increased risk [21] .
The associations between EPA/DHA and prostate cancer were not significant in the analyses of more advanced disease and disease at younger ages. This suggests that detection bias may be involved-men reporting higher levels of EPA/DHA intakes may be more health-conscious, and may therefore be more likely to visit a doctor. This could lead to a higher chance of early diagnosis. On the other hand, the trend for total prostate cancer was still significant after exclusion of asymptomatic cases.
Another possibility is Berksonian bias [42] -in this case, health-conscious men could conceivably have a greater chance of surviving long enough for a detectable prostate cancer to develop. However, in a post-hoc analysis, EPA/DHA intake was still significantly associated with increased total risk of prostate cancer even after adjusting for all variables significantly associated with mortality (data not shown).
Finally, it is of course always possible that the finding is either an effect of residual confounding, or a spurious result of multiple comparisons.
We observed no association between risk of prostate cancer and ALA intake. The relative validity of the MDC dietary assessment method is generally very good, compared to methods used in similar studies [43] . However, the relative validity of ALA (and LA) intake in men is comparatively low in the MDC study. The most important sources of ALA (and LA) are fats and vegetable oils. It is likely that many participating men did not know the type of fats used in the cooking of their meals or which brand of butter/margarine spread was used on their sandwiches. Due to the highly variable fatty acid composition of these fats, this might have resulted in misclassification. Thus, our findings on ALA and prostate cancer risk can hardly be said to either support or contradict an association.
Similar validity problems exist with regard to EPA/ DHA intakes. As noted above, the dominant source of EPA a An advanced case was defined as being either stage T3+ or N1 or M1or having a Gleason score of 8+ or having a prediagnostic serum PSA value of at least 50 ng/mL or being of WHO grade 3 in the absence of a Gleason score (see Methods). b Age, diabetes, waist circumference, height, living alone/with partner/with other (categorical), educational level (ordinal), alcohol habits (categorical), BMI (categorical), smoking history (ordinal), birth country (Sweden/other; categorical), total calcium intake, consumption of fruits, vegetables, and red meat. All dietary variables were energy-adjusted. c 65 men had missing values for one or more of the included variables. Therefore, the total number of cases was reduced to 280 in these analyses. b Age, diabetes, waist circumference, height, living alone/with partner/with other (categorical), educational level (ordinal), alcohol habits (categorical), BMI (categorical), smoking history (ordinal), birth country (Sweden/other; categorical), total calcium intake, consumption of fruits, vegetables, and red meat. All dietary variables were energy-adjusted c 65 men had missing values for one or more of the included variables. Therefore, the total number of cases was reduced to 814 in these analyses and DHA is fatty fish. The diet method was designed to capture information on main courses by having them registered for one consecutive week, but most consumers of fatty fish in Malmö do not have it every week. This could lead to misclassification. Further, participants may not always know the kind of fish consumed during the sevenday registration. However, it must be stressed that a low validity normally does not distort measured associations; instead, it tends to make them weaker. Thus, the positive association between EPA/DHA intake and prostate cancer in this study is probably not directly caused by low validity. It might seem strange that the cancer cases were younger than the non-cases at screening in the \65 subcohort (Table 1) . However, this result is most likely an artifact produced by differences in follow-up time. The average follow-up time in men aged 45-49 was around 4,500 days, compared to only 900 days for those aged 60-64, since the latter group obviously were much closer to the censoring point, their 65th birthday. Therefore, even if the relative risk in the older group was much higher than in the younger groups, the absolute risk was smaller.
We did not observe any significant associations between fat intake and advanced or younger-age cancer. The findings in these groups were mostly similar to those in the overall group, but since there were far fewer cases in these groups than in the total prostate cancer group, the statistical power was obviously correspondingly lower. Further, several PUFA variables suffered from low relative validity in men, which also lowers power.
Conclusions
This large prospective study showed no association between incidence of total and advanced prostate cancer and intake of total, saturated and mono-unsaturated fat. We found no evidence of a protective role of EPA or DHA in total or advanced prostate cancer; indeed, we observed a modestly increased risk of total prostate cancer at higher intakes, a result we find difficult to interpret. We found no support for a causative role of ALA, but for this fatty acid, the validity of our dietary method is suboptimal. Finally, we observed no association between fat intake and incidence of advanced prostate cancer, or prostate cancer in men \65 y.
